| Bioactivity | LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3]. | ||||||
| Invitro | LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery[1]. LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand[2]. | ||||||
| Name | LXW7 TFA | ||||||
| Sequence | Cys-Gly-Arg-Gly-Asp-Asp-Val-Cys-NH2 (Disulfide bridge:Cys1-Cys8) | ||||||
| Shortening | CGRGDDVC-NH2 (Disulfide bridge:Cys1-Cys8) | ||||||
| Formula | C31H49F3N12O14S2 | ||||||
| Molar Mass | 934.92 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |